Pathogenic Th17 cells orchestrate mucosal inflammation and drive secondary loss of response to infliximab in inflammatory bowel disease: clinical and mechanistic evidence

International Immunopharmacology 2026

View at publisher
Authors: Geng Li, Zhe Lin, Hui Cao, Jiemin Hong
DOI: 10.1016/j.intimp.2026.116473
Cited by: 2
References: 31

Fields of Study & Subjects

Inflammatory Bowel Disease Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments

Publication details

Journal / source
International Immunopharmacology
Publisher
Elsevier BV
Volume
176
Pages
116473–116473
Publication date
9 March 2026
Language
EN